Industry news that matters to you.  Learn more

ImaginAb and Duke-NUS Launch Imaging Biomarker Development Lab (IBDL)

ImaginAb, Inc. recently announced that it has entered into a partnership with the Duke-NUS Graduate Medical School Singapore (Duke-NUS) to establish a joint corporate laboratory to develop new in vivo molecular imaging agents to study cancer biology and immune function. ImaginAb is a U.S. clinical-stage company that develops in vivo molecular imaging agents based on a proprietary antibody fragment technology platform. ImaginAb’s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging.